Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel diseaseOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared gut microbiota in 16 patients with untreated, recent-onset psoriatic arthritis (PsA), 15 patients with skin psoriasis alone, and 17 healthy matched controls. All PsA patients were treatment-naive, with a mean disease duration under one month.
How was it studied?
Fecal samples underwent high-throughput 16S rRNA pyrosequencing to profile bacterial community composition and diversity. Investigators also measured fecal and serum secretory IgA, RANKL, osteoprotegerin, S100 protein, and short- and medium-chain fatty acids.
What did they find?
Bacterial diversity (Shannon and Faith indices) was significantly lower in PsA and psoriasis samples than in healthy controls. Coprococcus was reduced in both patient groups, while PsA samples specifically showed significant reductions in Akkermansia, Ruminococcus, and Pseudobutyrivibrio. PsA patients also had higher fecal secretory IgA, lower fecal RANKL, and reduced fecal hexanoate and heptanoate compared to controls.
Why it matters
The PsA gut microbiota profile resembled dysbiosis previously reported in inflammatory bowel disease, with depletion of taxa considered beneficial for gut barrier and immune homeostasis. The authors conclude this dysbiosis, distinct from psoriasis alone, merits further study in psoriasis-to-PsA disease progression.